{
  "$schema": "folio-library-entry/v1",
  "id": "10665-350214",
  "blocks": [
    {
      "id": "library/10665-350214/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Photograph, seen from behind, of a woman in a turquoise dress carrying an infant in a red knitted hat and blue blanket over her shoulder; the infant looks at the camera.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 2,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "POLICY BRIEF\nCOMPREHENSIVE PACKAGE OF CARE \nFOR INFANTS AND YOUNG CHILDREN \nEXPOSED TO HIV\n2021\n© UNICEF UNI221734 / Gonzalez Farran",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover of the 2021 policy brief on a comprehensive package of care for infants and young children exposed to HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "POLICY BRIEF",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/sec-000-policy-brief.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "COMPREHENSIVE PACKAGE OF CARE FOR INFANTS AND YOUNG CHILDREN EXPOSED TO HIV",
      "pageStart": 2,
      "pageEnd": 4,
      "target": "../sections/sec-001-comprehensive-package-of-care-for-infants-and-yo.md",
      "narrative": null,
      "content": "FOR INFANTS AND YOUNG CHILDREN \nEXPOSED TO HIV\n2021\nComprehensive package of care for infants and young children exposed to HIV: policy brief\nISBN 978-92-4-004023-6 (electronic version)\nISBN 978-92-4-004024-3 (print version)\n© World Health Organization 2021\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence \n(CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work \nis appropr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The title and copyright page of WHO's 2021 policy brief on comprehensive care for infants and young children exposed to HIV, giving ISBNs, the Creative Commons licence terms, citation and cataloguing details. It also includes the standard WHO disclaimers and layout credit.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "3TC",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-002-3tc.md",
      "narrative": null,
      "content": "lamivudine\nART\t\nantiretroviral therapy\nARV\t\nantiretroviral\nAZT\t\nzidovudine\nCTX\t\nCo-trimoxazole",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The start of the list of abbreviations, covering several antiretroviral drug names, therapy terms and co-trimoxazole.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "LPV/r",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-003-lpvr.md",
      "narrative": null,
      "content": "lopinavir/ritonavir\nNAT\t\nNucleic acid testing\nNNRTI\t\nnon-nucleoside reverse-transcriptase inhibitor\nNVP\t\nnevirapine\nPNP\t\npostnatal prophylaxis\nRAL\t\nraltegravir\nUNICEF\t\nUnited Nations Children’s Fund",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the list of abbreviations with further antiretroviral drugs, nucleic acid testing, postnatal prophylaxis and UNICEF.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABBREVIATIONS",
      "pageStart": 4,
      "pageEnd": 5,
      "target": "../sections/sec-004-abbreviations.md",
      "narrative": null,
      "content": "This policy brief was developed by Ivy Kasirye (Consultant, WHO) and Catherine Wedderburn (Consultant, WHO),  \nwith technical oversight by Martina Penazzato and Morkor Newman Owiredu of the Department of Global HIV, Hepatitis \nand Sexually Transmitted Infections Programmes of WHO, in collaboration with UNICEF, Elizabeth Glaser Pediatric AIDS \nFoundation and ICAP at Columbia University.\nWHO gratefully acknowledges the technical input of the external peer reviewers: Elaine Abrams and Nandita Sugandhi \n(ICAP at Columbia University, USA), George Alemji, Chelsea Solmo, Michelle Zavila, Michelle Che",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the consultants who wrote the policy brief, the WHO staff who oversaw it and the partner organizations and external experts who contributed technical input.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "BACKGROUND",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-005-background.md",
      "narrative": null,
      "content": "of HIV, the targets for maternal antiretroviral therapy \n(ART) coverage and new vertical transmission have \nyet to be achieved (1). Globally, an estimated 85% of \npregnant women living with HIV were receiving lifelong \nART, and 150 000 infants acquired HIV through vertical \ntransmission in 2020. Although more than 84% of vertical \ntranmissions occur in sub-Saharan Africa, it is encouraging \nthat eastern and southern Africa (the epicentre of the HIV \npandemic) has sustained maternal antiretroviral (ARV) \ncoverage rates of ≥90% since 2014 (1). Nevertheless, \npersisting challenges remain in preve",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the background to the policy brief, noting progress in preventing vertical HIV transmission but missed targets, with an estimated 85% of pregnant women living with HIV on treatment and 150 000 infants acquiring HIV in 2020. It stresses the need to reduce transmission risk and to support child survival, growth and development.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Justification for the comprehensive package of care for infants and young children exposed to HIV",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-006-justification-for-the-comprehensive-package-of-c.md",
      "narrative": null,
      "content": "of care for infants and young children \nexposed to HIV\nA systematic review revealed that 49% of women living with \nHIV in sub-Saharan Africa are lost between antenatal care \nregistration and delivery, 34% of infants exposed to HIV \nare lost to follow-up by three months and a further 45% of \ninfants exposed to HIV are lost after their first HIV test and \nbefore definitive diagnosis (13). This highlights significant \nattrition along the continuum between identifying HIV \namong pregnant women, initiating treatment to prevent \nvertical transmission and improve maternal health, initiating \nprophyla",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Justifies a comprehensive package of care by citing high losses of mothers and HIV-exposed infants between antenatal care, delivery, early testing and final diagnosis. It argues that an integrated package eases navigation for mothers and children and improves access to services for HIV-free survival.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview of the interventions along the continuum of care",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/sec-007-overview-of-the-interventions-along-the-continuu.md",
      "narrative": null,
      "content": "the continuum of care\nChildren younger than two years typically receive well-\nchild visits for routine services, including immunization, \nmonitoring growth and development, micronutrient \nsupplementation, deworming, preventing and managing \ncommon childhood conditions as well as infant feeding \ncounselling and support. In addition to these routine \nservices, infants and young children exposed to HIV \nshould receive specific services in a comprehensive \npackage as outlined below.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that children under two routinely receive well-child services such as immunization, growth monitoring and feeding counselling, and that HIV-exposed infants also need a specific package of care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Components of the comprehensive package of care for infants and young children exposed to HIV",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/sec-008-components-of-the-comprehensive-package-of-care.md",
      "narrative": null,
      "content": "of care for infants and young children \nexposed to HIV\nThe comprehensive package of care brings together \ninterventions across the continuum of care that \ncollectively aim to reduce the risk of vertical transmission \nof HIV and improve the health and well-being of infants \nand young children exposed to HIV. The package includes \nboth maternal and infant components (Fig. 1):\n• \u0007maternal HIV testing and retesting: other prevention \ninterventions for HIV-negative mothers are highly \nrelevant (2):\n• maternal ART, adherence counselling and monitoring;\n• \u0007infant diagnosis;\n• infant ARV prophylaxis;",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the maternal and infant components of the comprehensive package of care, from maternal HIV testing, treatment and monitoring to infant diagnosis, antiretroviral and co-trimoxazole prophylaxis, postnatal care, infant feeding and nurturing care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope",
      "pageStart": 6,
      "pageEnd": 7,
      "target": "../sections/sec-009-scope.md",
      "narrative": null,
      "content": "Although the comprehensive package of care \nincludes maternal, infant and young child \ninterventions, this policy brief focuses mainly on \nthe service package for infants and young children \nup to two years of age who are exposed to HIV. \nIt emphasizes the maternal interventions that \ndirectly affect decision-making for interventions \nfor the infants and young children exposed to \nHIV. For the detailed interventions for preventing \nvertical transmission, including combination \nHIV prevention for pregnant and breastfeeding \nwomen at risk of acquiring HIV, see the 2021 \nWHO consolidated guidelin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the scope of the policy brief as care for HIV-exposed infants and young children up to two years, with emphasis on maternal interventions that shape decisions about infant care. It excludes a full service package for children living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p007-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../images/img-p007-1.webp",
      "narrative": "draft",
      "content": "Photograph of a smiling woman pressing her cheek against a baby in an orange outfit whom she holds up.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p007",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../figures/vfig-p007.webp",
      "narrative": "draft",
      "content": "Figure 1, a target (bullseye) diagram with six arrows pointing to its centre, each labelled with a component of the comprehensive package of care for infants and young children exposed to HIV: infant diagnosis, postnatal care, postnatal prophylaxis, maternal testing, treatment and monitoring, nurturing care, and co-trimoxazole. Each label carries a short description, e.g. timely provision of co-trimoxazole to prevent Pneumocystis jirovecii pneumonia and mortality among infants and children living with HIV.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-010-hiv.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Infant diagnosis",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-011-infant-diagnosis.md",
      "narrative": null,
      "content": "Timely identification of infants living \nwith HIV by testing multiple times and \nensuring infant diagnosis",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes infant diagnosis as identifying infants living with HIV promptly through repeated testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Postnatal care",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-012-postnatal-care.md",
      "narrative": null,
      "content": "Routine postnatal care, including \nimmunization, growth and \ndevelopment monitoring, infant \nfeeding counselling and support",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes routine postnatal care, including immunization, growth and development monitoring and infant feeding support.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maternal testing, treatment and monitoring",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-013-maternal-testing-treatment-and-monitoring.md",
      "narrative": null,
      "content": "and monitoring\nIdentifying mothers through antenatal \ncare and maternal, newborn and child \nhealth services, ensuring that they start \nART and remain virally suppressed",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes maternal testing, treatment and monitoring as finding mothers through antenatal and child health services and keeping them on treatment with suppressed viral loads.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Postnatal prophylaxis",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-014-postnatal-prophylaxis.md",
      "narrative": null,
      "content": "Timely provision of ARV drugs to prevent \nHIV acquisition for all infants exposed, with \nparticular attention to those at high risk",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes postnatal prophylaxis as timely antiretroviral drugs for all HIV-exposed infants, with attention to those at high risk.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Co-trimoxazole",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-015-co-trimoxazole.md",
      "narrative": null,
      "content": "Timely provision of co-trimoxazole to prevent \nPneumocystis jirovecii pneumonia and mortality \namong infants and children living with HIV",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes co-trimoxazole provision to prevent Pneumocystis pneumonia and deaths among infants and children living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Nurturing care",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-016-nurturing-care.md",
      "narrative": null,
      "content": "Implementing simple interventions to \npromote early childhood development \nat the facility and in the community\nBox 1. Infants and young children living with \nHIV\nIf an infant or young child is confirmed to be \nliving with HIV during the period of follow-\nup, the early infant diagnosis cascade will have \nreached a final endpoint. If the infant is still on \nARV drug prophylaxis, this should be stopped, \nand ART initiated with the recommended triple \nARV drug first-line ART regimen (Fig. 3). \nWHO recommends early or same-day initiation \nof ART with an age-appropriate ART regimen \nonce the HIV di",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes nurturing care as simple interventions to promote early childhood development, and explains in a box that infants confirmed to have HIV should stop prophylaxis and start ART. A figure outlines components such as responsive caregiving, early learning, nutrition and maternal mental health.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p008",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../figures/vfig-p008.webp",
      "narrative": "draft",
      "content": "Figure 2, a timeline from 34–36 weeks' gestation to 24 months showing when each service is delivered: viral load tests for mothers living with HIV, retesting of HIV-negative high-risk mothers, and for exposed infants infant diagnosis (ID: nucleic acid tests at birth, 6 weeks and 9 months, serology at 18 months), co-trimoxazole (CTX), postnatal prophylaxis (PNP) for high- and low-risk infants, nurturing care (NC) and routine immunization and monitoring. Text boxes note that HIV infection is excluded with an appropriate test 3 months after stopping breastfeeding, and that co-trimoxazole and extended PNP may be stopped once HIV infection is excluded at the end of the at-risk period.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p009",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../figures/vfig-p009.webp",
      "narrative": "draft",
      "content": "Figure 3, a flow diagram (printed rotated on the page) of how the components of the package change after a child acquires HIV. Five components (ID, CTX, PNP, NC, Routine) lead into 'HIV-positive diagnosis', after which ART starts and continues lifelong; co-trimoxazole continues for all infants and children to 5 years of age; nurturing-care interventions run to 3, 5 and 8 years of age; and routine services to 2 years. After age 5, co-trimoxazole continues in settings with a high prevalence of malaria and severe bacterial infections (reassessment in adulthood) and may be discontinued in low-prevalence settings if the child is on ART, stable and virally suppressed.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PNP",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-017-pnp.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "NC",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-018-nc.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CTX",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-019-ctx.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV-POSITIVE DIAGNOSIS",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-020-hiv-positive-diagnosis.md",
      "narrative": null,
      "content": "HIV-POSITIVE DIAGNOSIS\n5 years of age",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of a figure showing the timeline after an HIV-positive diagnosis, with a five-year age marker.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ART",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-021-art.md",
      "narrative": null,
      "content": "All infants and children regardless \nof clinical or immune conditions\nAll children in settings with a high prevalence \nof malaria and severe bacterial infections\n8 years of age\n3 years of age\nReassessment \nin adulthood\nLifelong",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of a figure on care timelines, indicating ART for all infants and children for life and co-trimoxazole use by age and malaria or bacterial infection setting.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Routine",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-022-routine.md",
      "narrative": null,
      "content": "2 years of age\nMay be discontinued if on ART, stable and\n viral load suppression in low-prevalence malaria \nand severe bacterial infection settings\nID: Infant diagnosis; CTX: Co-trimoxazole; PNP: postnatal prophylaxis; NC: Nurturing care; N: Nucleic acid test; S: Serology test\nMaternal viraemia during pregnancy and the breastfeeding \nperiod significantly increases the risk of vertical HIV \ntransmission (23,24). Evidence shows that perinatal HIV-1 \ntransmission is virtually zero in mothers who start ART \nbefore conception, maintain viral load suppression through \npregnancy and have viral load <",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the figure's key and when co-trimoxazole may stop, then describes how maternal viraemia during pregnancy and breastfeeding drives vertical HIV transmission. It lists measures to reduce this risk, including treatment adherence and continuity of care for mothers and infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p010",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../figures/vfig-p010.webp",
      "narrative": "draft",
      "content": "Figure 4, a single stacked bar for 2020 (y-axis 0 to 160 000) showing infants acquiring HIV vertically by cause of transmission: mother acquired HIV during pregnancy or breastfeeding, 35 000; mother did not receive antiretroviral therapy during pregnancy or breastfeeding, 65 000; mother did not continue with treatment, 38 000; mother was on antiretroviral therapy but not virally suppressed, 14 000. Source: UNAIDS epidemiological estimates, 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007MATERNAL HIV TESTING, TREATMENT AND MONITORING",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-023-1-maternal-hiv-testing-treatment-and-monitoring.md",
      "narrative": null,
      "content": "AND MONITORING\nFig. 4. Infants acquiring HIV vertically by cause of transmission, global, 2020\nSource: UNAIDS epidemiological estimates, 2021 (1).\nMother acquired HIV during pregnancy  \nof breastfeeding\nMother did not receive antiretroviral therapy during \npregnancy or breastfeeding \nMother did not continue with treatment during \npregnancy or breastfeeding\nMother was on antiretroviral therapy but not virally \nsuppressed\n160 000\n140 000\n120 000\n100 000\n80 000\n60 000\n40 000\n20 000\n0\n14 000\n38 000\n65 000\n35 000\n2020",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A chart of infants acquiring HIV through vertical transmission globally in 2020 by cause, such as mothers infected during pregnancy or breastfeeding, not on ART, stopping treatment or not virally suppressed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maternal HIV testing and retesting",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-024-11-maternal-hiv-testing-and-retesting.md",
      "narrative": null,
      "content": "Preventing unplanned pregnancy and HIV acquisition, \nconfirming HIV status before pregnancy, early \nidentification of HIV infection during pregnancy and \nbreastfeeding and timely initiation of ART are critical \nfor minimizing vertical HIV transmission. All pregnant \nwomen should be offered HIV testing at the earliest \nopportunity during pregnancy and, if HIV positive, same-\nday initiation of ART. HIV re-testing and partner testing \nare important for women who initially test HIV negative, \nsince seroconversion during pregnancy and breastfeeding \nis increasingly becoming an important source of H",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses early HIV testing in pregnancy with same-day ART for women who test positive, and retesting and partner testing for those at risk. It recommends third-trimester retesting for women of unknown or HIV-negative status in high-burden settings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Settings with a high burden of HIV infection",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-025-settings-with-a-high-burden-of-hiv-infection.md",
      "narrative": null,
      "content": "settings, retesting should be based on risk, emphasizing \nthe need for ongoing risk screening (Box 2). An additional \nretest at 14 weeks, six months or nine months postpartum \nmay be considered for HIV-negative women at elevated \nrisk of acquiring HIV in settings with a high or low burden \nof HIV infection. The suggested times for postpartum \nretesting consider the opportunity provided when the \nmother has contact with the health system, especially \nwhen the child is brought in for immunization (2).\nBox 2. Suggested optimal retesting frequency for pregnant and breastfeeding women \nSettings wit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes HIV retesting in high-burden settings and risk-based retesting in low-burden settings, including an optional postpartum retest for women at elevated risk. It notes that suggested timings coincide with health service contacts and should prioritize high-incidence areas and key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Settings with a low burden of HIV infection",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-026-settings-with-a-low-burden-of-hiv-infection.md",
      "narrative": null,
      "content": "Retest pregnant women with unknown or HIV-negative status who are in serodiscordant relationships, \nwhose partner does not have suppressed viral loads on ART or who have other known ongoing HIV risk in late \npregnancy – at a third-trimester visit. If either the first test or retest is missed or delayed, catch-up testing is \nneeded. An additional postpartum retest for women of unknown or HIV-negative status can be considered for \nwomen from key populations or women who have partners with HIV who do not have suppressed viral loads. \nCountries could also consider an additional postpartum test in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the guidance for low-burden settings on retesting pregnant women at ongoing risk in late pregnancy, catch-up testing when tests are missed and optional postpartum retesting for key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-027-implementation-considerations.md",
      "narrative": null,
      "content": "Strategies to improve early identification of maternal \nHIV infection should include activities that promote early \ninitiation of antenatal services, attending all recommended \nantenatal visits and promoting facility deliveries. Health \nsystem interventions to improve the utilization and quality \nof antenatal care include:\n• \u0007woman-held case notes to improve the continuity  \nand quality of care and pregnancy experience;\n• \u0007midwife-led continuity-of-care models that support \nwomen throughout the antenatal to postnatal continuum;\n• group antenatal care;\n• \u0007community-based interventions to improv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists strategies to identify maternal HIV earlier by promoting early and complete antenatal care and facility births, including woman-held case notes and midwife-led continuity of care. It suggests high-prevalence countries consider routine postnatal retesting for all women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Time points",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-028-time-points.md",
      "narrative": null,
      "content": "retesting should be based on local context.\nTable 1. Recommended times for HIV retesting for pregnant and postpartum women\nSource: WHO consolidated guidelines on HIV testing services, 2019 (29).\nFurther guidance on HIV testing during pregnancy and postpartum is available (2).\nTime points\nSetting\nEarly in pregnancy  \n(first antenatal care visit)\nLate in pregnancy  \n(third-trimester  \nantenatal care visit)\nOne additional postpartum \nretest (14 weeks, 6 months  \nor 9 months postpartum)\nSettings with a high HIV \nburden\nAll\nAll\nCan be considered for  \nthose with ongoing high risk\nSettings with a lo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of recommended times for HIV retesting of pregnant and postpartum women in different settings, from the first antenatal visit to the third trimester and postpartum.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Recommended times for HIV retesting for pregnant and postpartum women",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "Recommended time points for HIV retesting of pregnant and postpartum women (early pregnancy, late pregnancy, one additional postpartum retest) in settings with a high HIV burden, settings with a low HIV burden, and among key population groups and their partners.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Viral load monitoring",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-029-12-viral-load-monitoring.md",
      "narrative": null,
      "content": "Viral load monitoring during pregnancy and the \nbreastfeeding period is recommended to identify women \nwho already have suppressed viral loads and to offer timely \nintervention to achieve viral suppression in women who \nare viraemic during the period of HIV transmission risk. \nThe 2021 WHO consolidated guidelines (2) recommend \nroutine viral load monitoring at six and 12 months after \ninitiating ART and every 12 months thereafter for all people \nliving with HIV (Annex 1). In addition to the routine viral \nload monitoring tests recommended for nonpregnant \nadults, additional viral load assessme",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends viral load monitoring during pregnancy and breastfeeding to identify women who need help achieving viral suppression, and summarizes WHO's routine monitoring schedule. It introduces a table on monitoring treatment for pregnant and breastfeeding women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Category",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-030-category.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Timing of viral load monitoring",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-031-timing-of-viral-load-monitoring.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Action",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-032-action.md",
      "narrative": null,
      "content": "Pregnant women receiving ART  \nbefore conception\nFirst antenatal care visit  \n(or when first presenting)\n• \u0007If viral load >1000 copies/mL, follow the \ntreatment monitoring algorithm (Fig.5) \nand consider infant nucleic acid testing \nat birth if available\nPregnant women starting ART  \nduring pregnancy\nThree months after initiating ART \n• \u0007If viral load >1000 copies/mL, follow the \ntreatment monitoring algorithm (Fig. 5)\n• \u0007Regardless of maternal viral load, infants \nborn to women starting ART at any time \nduring pregnancy could be considered \nfor birth testing if available\nAll pregnant women, r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of actions for viral load testing in pregnant women, depending on whether they started ART before or during pregnancy, including following the monitoring algorithm and considering infant testing at birth.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Monitoring treatment for pregnant and breastfeeding women",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "Viral load monitoring for pregnant and breastfeeding women on ART: for each category of woman the table gives when viral load should be measured and what action to take if it exceeds 1000 copies/mL, including infant testing and postnatal prophylaxis.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p014-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../images/img-p014-1.webp",
      "narrative": "draft",
      "content": "Photograph of a woman in an orange headscarf and a blue face mask holding a baby in a white shirt.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Point-of-care viral load testing",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-033-point-of-care-viral-load-testing.md",
      "narrative": null,
      "content": "Evidence suggests that point-of-care viral load testing has \nthe capacity to improve access to viral load testing, reduce \nturnaround time for results to the clinician, increase the \nprobability of same-day results, improve the timeliness  \nof clinical action to address elevated viral load and increase \ncontinuity of treatment and viral suppression (30–32). \nPoint-of-care testing should be considered especially for \npregnant and breastfeeding mothers for whom rapid test \nresults are critical for decision-making.\nIntegrating point-of-care viral load technologies to \ncomplement laboratory capaci",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out evidence that point-of-care viral load testing improves access, speeds results and helps continuity of treatment, and recommends prioritizing it for pregnant and breastfeeding women. It lists requirements such as quality assurance, supply chains and maintenance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-034-implementation-considerations.md",
      "narrative": null,
      "content": "Viral load testing capacity and coverage should be \nexpanded by scaling up laboratory viral load testing \ninfrastructure; strengthening the efficiency of sample \nprocessing and transport systems; supporting community \nviral load sample collection and testing using dried blood \nspot or plasma separation card and establishing networks \nfor point-of-care viral load testing to improve access \non the maternal; newborn and child health platform and \nenable monitoring of pregnant and breastfeeding women \nreceiving ART. It will also be important to establish and \ndisseminate clear protocols for viral",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends expanding viral load testing through laboratory capacity, sample transport, dried blood spot collection and point-of-care networks. It then describes the early infant diagnosis schedule, including testing at six weeks, after breastfeeding exposure and serology at 18 months.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Early infant diagnosis for high-risk infants",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-035-early-infant-diagnosis-for-high-risk-infants.md",
      "narrative": null,
      "content": "Nucleic acid testing at birth may be considered for high-\nrisk infants. In addition, infants who are first identified as \nHIV-exposed postpartum have a high cumulative risk of \nalready having acquired HIV by the time prophylaxis is \ninitiated. Under these circumstances, HIV nucleic acid \ntesting should be performed and presumptive treatment \nstarted to avoid extended prophylaxis among infants who \nare already HIV infected (see infant ARV prophylaxis).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Suggests that high-risk infants may be offered nucleic acid testing at birth, and that infants first found to be exposed after delivery should be tested and started on presumptive treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Point-of-care infant diagnosis",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-036-point-of-care-infant-diagnosis.md",
      "narrative": null,
      "content": "Access to early infant diagnosis remains low, with only \n60% of infants exposed to HIV globally tested by the \nsecond month of age in 2020 (39). Even when infants \nare tested, delays in receiving test results and weak \nlinkage to ART contribute to attrition along the testing-\nto-treatment cascade. Evidence suggests that point-of-\ncare nucleic acid testing enables more rapid testing with \nreturn of results to caregivers and clinicians; increased \ncontinuity in the testing-to-treatment cascade; fewer \nhealth facility visits for caregivers to receive results; \nmore reliability in the timing of re",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that only 60% of HIV-exposed infants were tested by two months of age in 2020, with delays in results and linkage to treatment. It describes evidence that point-of-care nucleic acid testing speeds results and treatment and calls for systematic follow-up of mother–baby pairs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007INFANT DIAGNOSIS",
      "pageStart": 15,
      "pageEnd": 17,
      "target": "../sections/sec-037-2-infant-diagnosis.md",
      "narrative": null,
      "content": "Box 4. WHO recommendation on point-of-\ncare infant diagnosis\nPoint-of-care nucleic acid testing should be \nused to diagnose HIV among infants and\nchildren younger than 18 months of age (strong \nrecommendation; high-certainty evidence).\nSource: Consolidated guidelines on HIV prevention, testing, treatment, service delivery \nand monitoring: recommendations for a public health approach, 2021 update (2).\nPoint-of-care infant diagnosis technologies should \nbe integrated within the existing infant diagnosis \nnetworks, with introduction and scale-up tailored to \nthe available resources and local cont",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents WHO's strong recommendation to use point-of-care nucleic acid testing to diagnose HIV in children under 18 months, with guidance on placing these technologies. It also covers infant feeding, noting that mothers on ART with suppressed viral loads can breastfeed up to two years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p016-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../images/img-p016-1.webp",
      "narrative": "draft",
      "content": "Photograph of a woman in a black head wrap and patterned pink dress holding a toddler who is eating from a packet, in front of a corrugated metal wall.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p017-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../images/img-p017-1.webp",
      "narrative": "draft",
      "content": "Photograph of a woman in a red patterned headscarf and a yellow cloth mask holding a smiling baby in a home, with shelves and a 2020 wall calendar behind them.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "INFANT ANTIRETROVIRAL PROPHYLAXIS",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-038-3-infant-antiretroviral-prophylaxis.md",
      "narrative": null,
      "content": "Box 5. WHO good practice statement\nART should be initiated before pregnancy and \nurgently among all pregnant and breastfeeding \nwomen living with HIV, even if they are identified \nlate in pregnancy or postpartum, because the \nmost effective way to reduce the risk of HIV \nvertical transmission is to suppress maternal viral \nload. Whenever possible, all efforts should be \nmade to identify HIV-infected pregnant women \nearly enough to avoid the need for enhanced \nprophylaxis.\nSource: Consolidated guidelines on HIV prevention, testing, treatment, service delivery \nand monitoring: recommendations fo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a WHO good practice statement that ART should start before or urgently during pregnancy and breastfeeding, since suppressing maternal viral load is the most effective way to prevent vertical transmission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Risk assessment of infants exposed to HIV",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-039-risk-assessment-of-infants-exposed-to-hiv.md",
      "narrative": null,
      "content": "Risk assessment is based on prevailing maternal factors \nthat affect the probability of HIV vertical transmission \nand is essential for selecting appropriate preventive \ninterventions for infants exposed to HIV. Infants exposed \nto HIV are considered to have low risk for vertical \ntransmission if their mothers are receiving ART and have \nsuppressed viral loads during pregnancy and delivery and \nthroughout breastfeeding.\nWHO defines high-risk infants as those (Fig. 5):\n• \u0007born to women with established HIV infection who have \nreceived less than four weeks of ART at the time of \ndelivery; or\n• \u0007",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how HIV-exposed infants are assessed as low or high risk of vertical transmission based on maternal treatment and viral load. Infants are low risk when mothers are on ART with suppressed viral loads, and WHO's definition of high-risk infants is given.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p018-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../images/img-p018-1.webp",
      "narrative": "draft",
      "content": "Photograph of a woman in a pink headscarf holding a baby in a white cap and striped top.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p018",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../figures/vfig-p018.webp",
      "narrative": "draft",
      "content": "Figure 5, a decision tree starting from 'Assess mother at delivery'. Infants are classed as high risk if the mother is a known HIV-positive mother not on ART, is newly identified as HIV-positive within 72 hours of delivery, or is on ART with a viral load above 1000 within 4 weeks before delivery; they are low risk if the viral load is at or below 1000. If no viral load result is available, infants are low risk when the mother has been on ART for more than 4 weeks before delivery and high risk otherwise.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antiretroviral prophylaxis",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-040-antiretroviral-prophylaxis.md",
      "narrative": null,
      "content": "Infants at low risk of vertical transmission should receive \na single ARV drug as postnatal prophylaxis for 4–6 weeks \n(Box 6).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that a single antiretroviral drug for four to six weeks is recommended as postnatal prophylaxis for infants at low risk of vertical transmission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Enhanced postnatal prophylaxis",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-041-enhanced-postnatal-prophylaxis.md",
      "narrative": null,
      "content": "Infants at high risk for vertical transmission should receive \ndual ARV drugs for six weeks followed by dual or single \nARV drugs for another six weeks for a total of 12 weeks \n(Box 6). When the recommended regimen is not available \nor feasible, alternative options such as RAL, 3TC, LPV/r \nsolid formulations or triple-drug fixed-dose combinations \ncontaining AZT, NVP and 3TC may be considered (see \nAnnex 1 for the dosing recommendations of ARV drugs \ncurrently used for infant prophylaxis).\nAssess mother AT DELIVERY\nYES:\nVL >1,000\nYES:\nVL ≤1,000\nHIGH \nRISK\nHIGH \nRISK\nHIGH \nRISK\nLOW \nRISK\nKnown",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes enhanced postnatal prophylaxis for high-risk infants using dual antiretroviral drugs for six weeks followed by six more weeks of dual or single drugs, with alternative regimens if needed. It gives the related WHO recommendation and its certainty of evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-042-implementation-considerations.md",
      "narrative": null,
      "content": "Various countries have adopted enhanced postnatal \nprophylaxis using a variety of approaches to adapt to the \ncountry context. A policy review conducted in 18 AIDS \nFree priority countries revealed that seven countries \nadopted enhanced postnatal prophylaxis for  \nall breastfeeding infants exposed to HIV and 11 countries \nfor only high-risk infants. Risk was determined primarily \nbased on the timing of maternal HIV diagnosis, whether \nthe mother was on ART, duration on ART before delivery, \nmaternal viral load at delivery and viral load during the \nbreastfeeding period. Five countries link the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports how 18 priority countries have adopted enhanced postnatal prophylaxis, some for all breastfeeding HIV-exposed infants and others only for high-risk infants. It advises providing infant prophylaxis in the same setting as maternal ART.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Providing enhanced postnatal prophylaxis to all infants exposed to HIV",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-043-providing-enhanced-postnatal-prophylaxis-to-all.md",
      "narrative": null,
      "content": "exposed to HIV\nThis may be considered in settings in which most \nmothers are at high risk of transmitting HIV because \nof poor maternal ART coverage, high rates of loss to \nfollow-up, poor maternal viral load testing coverage and \npoor maternal viral suppression rates. It should serve as \nan interim measure as strategies to improve maternal \nART coverage, maternal viral load testing coverage \nand maternal viral suppression rates are put in place. \nAlthough this approach offers a safety net, it may lead to \nincreased costs and strained ARV drug stocks and may \nunnecessarily expose infants who d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes giving enhanced prophylaxis to all HIV-exposed infants as an interim measure where maternal ART and viral suppression are poor, noting the trade-offs of cost, drug supply and unnecessary toxicity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Extended or prolonged postnatal prophylaxis beyond",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-044-extended-or-prolonged-postnatal-prophylaxis-beyo.md",
      "narrative": null,
      "content": "12 weeks\nAlthough limited evidence suggests additional benefit \nof combination or prolonged regimens in the context of \nmaternal ART (44), infants and young children who remain \nat high risk for HIV transmission during the breastfeeding \nperiod may receive extended prophylaxis until the risk \nis considered limited or has ended. Circumstances that \npresent persistent risk to breastfeeding infants beyond the \nrecommended 12 weeks of prophylaxis include: maternal \nunwillingness or inability to start or continue ART, poor \nmaternal adherence, documented maternal viraemia \nwhen the infant prophylax",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses extended prophylaxis beyond 12 weeks for infants still at high risk during breastfeeding, listing circumstances of persistent risk. It advises against restarting prophylaxis once stopped and favours support for maternal adherence instead.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p020-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../images/img-p020-1.webp",
      "narrative": "draft",
      "content": "Photograph of a woman leaning over a toddler girl who holds pink and orange plastic cups, against a blue background.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Presumptive treatment",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-045-presumptive-treatment.md",
      "narrative": null,
      "content": "Infants may be identified as exposed to HIV late when \nthey present for health services outside the prevention-\nof-vertical-transmission cascade. Their mothers may be \ndiagnosed with HIV late or may have acquired HIV during \nthe breastfeeding period. These infants are at high risk of \nvertical transmission because of high levels of maternal \nviraemia and the absence of maternal ART. Under these \ncircumstances, nucleic acid testing should be performed \nat the earliest opportunity and presumptive treatment with \na triple-ARV drug regimen at therapeutic doses initiated. \nThis approach will reduce",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes presumptive treatment for infants identified as HIV-exposed late, whose mothers were diagnosed late or infected while breastfeeding, involving nucleic acid testing and starting treatment straight away. It notes how the regimen should be adjusted after results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CO-TRIMOXAZOLE PROPHYLAXIS",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-046-4-co-trimoxazole-prophylaxis.md",
      "narrative": null,
      "content": "Co-trimoxazole prophylaxis was first introduced in the \nWHO guidelines in 2006 as a component of standard \nHIV care, primarily as prophylaxis for Pneumocystis \njirovecii pneumonia and toxoplasmosis for people living \nwith HIV and infants exposed to HIV until it could be \nreliably established that they were HIV-uninfected (46). \nIn subsequent years, the use of co-trimoxazole prophylaxis \nwas extended to preventing malaria and severe bacterial \ninfections among people living with HIV in settings with a \nhigh prevalence of these conditions. Evidence has shown \nsignificant decrease in morbidity an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the history of co-trimoxazole prophylaxis in WHO guidelines since 2006, from preventing Pneumocystis pneumonia and toxoplasmosis to preventing malaria and severe bacterial infections. It presents the current recommendation for HIV-exposed infants and children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Population",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-047-population.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Criteria for initiating co-trimoxazole prophylaxis",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-048-criteria-for-initiating-co-trimoxazole-prophylax.md",
      "narrative": null,
      "content": "co-trimoxazole prophylaxis",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table column heading for criteria for initiating co-trimoxazole prophylaxis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Criteria for discontinuing co-trimoxazole prophylaxis",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-049-criteria-for-discontinuing-co-trimoxazole-prophy.md",
      "narrative": null,
      "content": "co-trimoxazole prophylaxis",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table column heading for criteria for discontinuing co-trimoxazole prophylaxis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Children and adolescents living with HIV",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-050-children-and-adolescents-living-with-hiv.md",
      "narrative": null,
      "content": "living with HIV\n• \u0007Initiate for everyone regardless of WHO \nclinical stage or CD4 cell count\n• \u0007As a priority:\n   – \u0007Initiate for everyone younger than five \nyears regardless of WHO clinical stage \nor CD4 cell count\n   – \u0007Initiate for everyone five years and \nolder with severe or advanced HIV \ndisease (WHO clinical stage 3 or 4)  \nor CD4 cell count ≤350 cells/mm3\n• \u0007In settings with high prevalence of malaria \nand/or severe bacterial infections: should \nnot be discontinued until adulthood\n• \u0007In settings with low prevalence of both \nmalaria and severe bacterial infections: \nmay be discontinued",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives criteria for starting and stopping co-trimoxazole in children and adolescents living with HIV, with priority for under-fives and those with advanced disease, and continuation in high malaria and bacterial infection settings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV-exposed infants",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-051-hiv-exposed-infants.md",
      "narrative": null,
      "content": "Initiate for everyone starting at 4–6 weeks \nafter birth\nUntil the risk of HIV transmission ends  \nand HIV infection is excluded with  \nage-appropriate testb\nTable 3. Criteria for initiating and discontinuing co-trimoxazole prophylaxis among children",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that co-trimoxazole should start for all HIV-exposed infants at four to six weeks and continue until HIV is excluded, as part of a table of initiation and discontinuation criteria.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. Criteria for initiating and discontinuing co-trimoxazole prophylaxis among children",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "Criteria for starting and stopping co-trimoxazole prophylaxis in two populations: children and adolescents living with HIV, and HIV-exposed infants.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-052-implementation-considerations.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Infants exposed to HIV and uninfected",
      "pageStart": 22,
      "pageEnd": 24,
      "target": "../sections/sec-053-infants-exposed-to-hiv-and-uninfected.md",
      "narrative": null,
      "content": "A systematic review was conducted to assess the effect \nof co-trimoxazole prophylaxis on the morbidity and \nmortality of infants who are HIV exposed and uninfected \n(51). Two trials were identified that addressed the \nresearch question. A randomized placebo-controlled trial \nin Botswana (52) that started co-trimoxazole at 14–34 \ndays and continued it until 15 months of age showed no \nevidence of benefit of co-trimoxazole for children who \nare HIV exposed and uninfected for cumulative mortality \nto 18 months, hospitalization, diarrhoea or pneumonia; \nneutropenia was more frequent in the co-trim",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews evidence on co-trimoxazole for infants who are HIV-exposed but uninfected, citing trials that found no clear benefit, and discusses how policies might be applied in different settings. It then turns to health and development, noting that HIV-exposed children are more likely to have motor and cognitive delays. It introduces nurturing care, including health, nutrition, security, responsive caregiving and early learning.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4. Summary table of evidence from the systematic review examining the effect of co-trimoxazole on the morbidity and mortality of infants who are HIV-exposed and uninfected",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "Evidence from a systematic review on co-trimoxazole prophylaxis in HIV-exposed uninfected infants, grouped into main studies, substudies on antibiotic resistance and microbiome, and studies from malarial countries. For each study the table gives country, numbers in each arm and the direction of effect (no difference, negative or positive) on mortality, hospital admission, diarrhoea, pneumonia, a combined outcome, malaria, neutropenia and anaemia.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p024-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../images/img-p024-1.webp",
      "narrative": "draft",
      "content": "Figure 6: Circular diagram of the five components of nurturing care around the central label 'Components of nurturing care': good health (green, heart icon), adequate nutrition (gold, bowl icon), responsive caregiving (blue, parents holding a baby), security and safety (dark blue, family under a sheltering arm) and opportunities for early learning (red, child playing).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/figure-vfig-p024",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../figures/vfig-p024.webp",
      "narrative": "draft",
      "content": "Figure 6: Circular diagram of the five components of nurturing care around the central label 'Components of nurturing care': good health (green, heart icon), adequate nutrition (gold, bowl icon), responsive caregiving (blue, parents holding a baby), security and safety (dark blue, family under a sheltering arm) and opportunities for early learning (red, child playing).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Responsive caregiving",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-054-responsive-caregiving.md",
      "narrative": null,
      "content": "and opportunities for early learning (Fig. 6), directly \naffects child development, supporting children to reach \ntheir full developmental potential.\nFig. 6. Components of nurturing care",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that nurturing care, including responsive caregiving and early learning, directly supports child development, with a figure of its components.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PROMOTING NURTURING CARE",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-055-5-promoting-nurturing-care.md",
      "narrative": null,
      "content": "Developmental assessments by direct measurement \nand observation are used to assess various aspects of a \nchild’s functioning and abilities (motor, sensory, cognition, \ncommunication, behaviour, social interaction and \nadaptive skills). Systematic and structured developmental \nassessments using standardized validated tools are \nadvised. Several age-dependent tools are used for formal \ndevelopmental assessment, including norm-referenced \ntests (comparing with peers) and criterion-reference \ntests (comparing with prespecified criteria). Assessment \nshould assess the child’s family environment. N",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes developmental assessments using standardized, validated tools to measure motor, cognitive, communication and social skills. It presents WHO's recommendation that all infants receive responsive care in their first three years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Promote early learning",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-056-promote-early-learning.md",
      "narrative": null,
      "content": "All infants and children should have early learning \nactivities with their parents and other caregivers \nduring the first three years of life; parents and \nother caregivers should be supported to engage in \nearly learning with their infants and children (strong \nrecommendation; moderate-quality evidence).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO's strong recommendation that all young children take part in early learning activities with caregivers during the first three years, with caregivers supported to do so.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-057",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Integrate caregiving and nutrition interventions",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-057-integrate-caregiving-and-nutrition-interventions.md",
      "narrative": null,
      "content": "Support for responsive care and early learning \nshould be included as part of interventions for \noptimal nutrition of infants and young children \n(strong recommendation; moderate-quality evidence).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO's recommendation to include support for responsive care and early learning in infant and young child nutrition interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-058",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Support maternal mental health",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-058-support-maternal-mental-health.md",
      "narrative": null,
      "content": "Psychosocial interventions to support maternal \nmental health should be integrated into early \nchildhood health and development services (strong \nrecommendation; moderate-quality evidence).\nSource: Improving early childhood development (60).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO's recommendation to integrate psychosocial support for maternal mental health into early childhood health and development services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-059",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-059-implementation-considerations.md",
      "narrative": null,
      "content": "Multistakeholder engagement and multisectoral approaches \nat the national and community levels to ensure local contexts \nand available supportive systems to implement nurturing \ncare interventions are considered critical to comprehensive \nservice delivery, uptake and sustainability. Programmes \nshould select validated tools that are appropriate for \nimplementation in the local context to identify infants and \nyoung children exposed to HIV with developmental delay \nor at risk for it for timely intervention. Training appropriate \ncadres to implement nurturing care activities at facilities \nand w",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for multistakeholder and multisectoral approaches to nurturing care, locally validated developmental screening tools and referral systems for infants exposed to HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-060",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "POLICY IMPLEMENTATION CONSIDERATIONS FOR THE COMPREHENSIVE PACKAGE OF CARE",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-060-policy-implementation-considerations-for-the-com.md",
      "narrative": null,
      "content": "to their specific contexts based on the level of implementation \nand capacities for the individual components, nevertheless \nendeavouring to ensure that all the components of care are \noptimally delivered jointly in a comprehensive approach.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises countries to adapt the comprehensive package of care to their capacity while still delivering all components together.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-061",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "National level",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-061-national-level.md",
      "narrative": null,
      "content": "The comprehensive integrated package of care for infants \nand young children exposed to HIV should be strategically \npositioned on reproductive, maternal, newborn, child and \nadolescent health platforms. Contextual assessment and \ninclusive multistakeholder engagement for operationalizing \nthis package of care will be critical. It will be important for \nprogramme leadership to ensure that the care package is \naligned with the relevant reproductive, maternal, newborn, \nchild and adolescent health guidelines, policies and service \ndelivery models and that there are adequate commodities, \nfunding",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends placing the package of care for HIV-exposed infants on reproductive, maternal, newborn, child and adolescent health platforms, aligned with related policies and backed by commodities, funding and coordination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-062",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Human resources",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-062-human-resources.md",
      "narrative": null,
      "content": "The potential challenges of introducing a new care \npackage within contexts of limited human resources and \ncapacity at the different levels of care need to be carefully \nconsidered. Existing networks, including lay and peer \nproviders and community health workers at facilities and \nin communities, provide opportunities for task sharing and",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that introducing the care package for HIV-exposed infants must account for limited staff capacity, and that lay and peer providers and community health workers offer scope for task sharing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-063",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Service delivery",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-063-service-delivery.md",
      "narrative": null,
      "content": "including psychosocial and adherence support, community \nfollow-up, sample collection, sample transport and drug \ndistribution. This will entail capacity building for the cadres \nengaged in the various components of the care package \nand, if possible, innovative technologies, tools and aids to \nfacilitate its implementation.\nService delivery\nThe comprehensive care package should be strategically \nintegrated on reproductive, maternal, newborn and child \nhealth platforms, including at primary health facilities. \nFacility protocols and standard operating procedures for \nclinical and laboratory se",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the human resources point, listing tasks such as psychosocial and adherence support, sample transport and drug distribution that could be shared, with capacity building and innovative tools. It then describes service delivery, recommending integration of the care package into reproductive, maternal, newborn and child health platforms, with standard procedures and synchronized appointments for mother–infant pairs. It also calls for community-based strategies to keep exposed infants in care through to final diagnosis and to maintain services during disasters and pandemics.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-064",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring, evaluation and learning",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-064-monitoring-evaluation-and-learning.md",
      "narrative": null,
      "content": "Determining priorities for monitoring and evaluating the \ncomprehensive package of care and identifying programme \nindicators are important for programmes. Priorities for \nmonitoring will include:\n• antenatal initiation and attendance;\n• postnatal attendance;\n• \u0007the number of pregnant and breastfeeding women living \nwith HIV disaggregated for timing of HIV diagnosis, \nmaternal ART coverage, maternal ART timing, maternal \nviral load coverage and maternal viral suppression rates;\n• \u0007the number of identified infants and young children \nexposed to HIV disaggregated for risk and time of \nidentifica",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists monitoring priorities for the care package for HIV-exposed infants, from antenatal and postnatal attendance and maternal ART and viral suppression to early infant diagnosis coverage and follow-up to final diagnosis. It also calls for implementation research to guide phased roll-out and for adequate funding and training of monitoring and evaluation staff.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-065",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Quality improvement",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-065-quality-improvement.md",
      "narrative": null,
      "content": "To ensure a safe, effective, patient-centred comprehensive \npackage of care for infants and young children who \nare HIV exposed, quality improvement can be used to \naddress gaps along the continuum of care. Quality can \nbe assessed to ensure that the standards of care are met \nand to minimize missed opportunities. Key to this will \nbe identifying quality indicators. Quality improvement \nteams and/or health-care providers can implement quality \nimprovement projects to systematically address gaps in the \npackage, especially access to services and optimal patient \noutcomes. Using a quality improv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes using quality improvement methods, quality indicators and client-led initiatives involving mothers to close gaps in care for HIV-exposed infants, particularly in decentralized, resource-limited settings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-066",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research gaps",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-066-research-gaps.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-067",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ARV drug prophylaxis",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-067-arv-drug-prophylaxis.md",
      "narrative": null,
      "content": "The additional benefit of combination or prolonged infant \nprophylaxis with maternal ART remains uncertain.  \nIn addition, limited evidence supports infant prophylaxis \nfor infants with HIV exposure identified during the \npostpartum period or the mother acquiring HIV during \npregnancy and the breastfeeding period. Research is \nneeded, including clinical and pharmacological studies, \nto inform the development of improved ARV drug \nformulations and to identify alternative drugs for \nprophylaxis that are well tolerated and that may have \ngreater efficacy for infant prophylaxis in case of prolonge",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies research gaps on antiretroviral prophylaxis for HIV-exposed infants, including the added value of combination or prolonged prophylaxis and prophylaxis when exposure is identified late or the mother acquires HIV after pregnancy begins. It also calls for better infant drug formulations and studies on maternal viraemia during breastfeeding and on defining high-risk infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-068",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Co-trimoxazole prophylaxis",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-068-co-trimoxazole-prophylaxis.md",
      "narrative": null,
      "content": "WHO anticipates fully reviewing the co-trimoxazole \nprophylaxis recommendation as further evidence is \ngathered and increasing progress is made, to rapidly \nidentify infants living with HIV and retaining those exposed \nto HIV in the testing cascade until final diagnosis is \nascertained. Research gaps remain about how to optimize \nthe use of co-trimoxazole prophylaxis, and well-conducted \noperational research will be critical to innovate and better \ninform co-trimoxazole prophylaxis for children in the \nfuture, including:\n\u0007• the optimal timing of initiation;\n• \u0007the clinical and programmatic imp",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that WHO expects to fully review its co-trimoxazole prophylaxis recommendation for HIV-exposed infants as evidence accumulates. It lists research questions such as optimal start timing, shorter duration, alternative antibiotics, antimicrobial resistance and effects on the microbiome.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-069",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Other gaps",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../sections/sec-069-other-gaps.md",
      "narrative": null,
      "content": "The impact of integrating nurturing care interventions \ninto service delivery for infants and young children \nexposed to HIV needs to be better understood.  \nThe impact of caregiver support interventions  may also \nneed to be further explored. Finally, more research on \nintegrated services is needed, especially to document \nthe impact of HIV services when integrated into routine \nchild services.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes further research needs on integrating nurturing care and caregiver support into services for HIV-exposed infants and on the impact of HIV services integrated into routine child health care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-070",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REFERENCES",
      "pageStart": 28,
      "pageEnd": 31,
      "target": "../sections/sec-070-references.md",
      "narrative": null,
      "content": "1. \u0007UNAIDS epidemiological estimates [online database]. Geneva: \nUNAIDS; 2021 (https://aidsinfo.unaids.org, accessed 27 \nSeptember 2021).\n2. \u0007Consolidated guidelines on HIV prevention, testing, \ntreatment, service delivery and monitoring: recommendations \nfor a public health approach, 2021 update. Geneva: World \nHealth Organization; 2021 update (https://apps.who.int/iris/\nhandle/10665/342899, accessed 27 September 2021).\n3. \u0007Shapiro R, Lockman S. Mortality among HIV-exposed infants: \nthe first and final frontier. Clin Infect Dis. 2010;50:445–7.\n4. \u0007Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, S",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the guidance on care of HIV-exposed infants and young children, citing UNAIDS estimates, WHO consolidated HIV guidelines and studies on outcomes, prophylaxis and child development.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-071",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007SIMPLIFIED AGE-BASED ANTIRETROVIRAL DRUG DOSING FOR ADMINISTERING ENHANCED AND PROLONGED POSTNATAL PROPHYLAXIS",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-071-annex-1-simplified-age-based-antiretroviral-drug.md",
      "narrative": null,
      "content": "ANTIRETROVIRAL DRUG DOSING \nFOR ADMINISTERING ENHANCED \nAND PROLONGED POSTNATAL \nPROPHYLAXIS\na\na \u0007In special circumstances with stock-outs of NVP and/or AZT, alternative ARV drugs could be used: RAL with treatment dosing, 3TC or LPV/r based on evidence \ngathered through the PROMISE trial (3TC was administered as follows: 7.5 mg once daily for neonates weighing 2 to <4 kg, 25 mg once daily for infants weighing 4 to \n<8 kg and 50 mg once daily for children weighing more than 8 kg; LPV/r was administered twice daily after the first week of life according to the following dosing scheme: \n40/10 mg",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex table giving simplified age-based dosing of nevirapine and zidovudine for enhanced and prolonged postnatal prophylaxis in HIV-exposed infants. Its notes describe alternative drugs, such as raltegravir, lamivudine or lopinavir/ritonavir, for use during stock-outs, and it is sourced from the 2021 WHO consolidated HIV guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-072",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007SIMPLIFIED DOSING OF CO- TRIMOXAZOLE PROPHYLAXIS FOR INFANTS AND CHILDREN AT LEAST FOUR WEEKS OLD",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-072-annex-2-simplified-dosing-of-co--trimoxazole-pro.md",
      "narrative": null,
      "content": "TRIMOXAZOLE PROPHYLAXIS FOR \nINFANTS AND CHILDREN AT LEAST \nFOUR WEEKS OLD",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The heading of an annex table on simplified co-trimoxazole prophylaxis dosing for infants and children aged four weeks or older; the table itself was not extracted.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-073",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007ANNEX 3. INFANT DIAGNOSIS ALGORITHM",
      "pageStart": 33,
      "pageEnd": 34,
      "target": "../sections/sec-073-annex-3-infant-diagnosis-algorithm.md",
      "narrative": null,
      "content": "Source: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World \nHealth Organization; 2021 update (https://apps.who.int/iris/handle/10665/342899, accessed 27 September 2021).\nNotes:\na. Based on 2016 WHO Consolidated ARV Guidelines, addition of NAT at birth to the existing testing algorithm can be considered.\nb. POC NAT can be used to diagnose HIV infection as well as to confirm positive results.\nc. \u0007Start ART without delay. At the same time, retest to confirm infection. As maternal",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3, the infant HIV diagnosis algorithm from the 2021 WHO consolidated guidelines, with notes on optional birth testing, point-of-care nucleic acid testing, starting ART immediately while confirming a positive result and the rising risk of false positives. It shows testing at set ages through to final diagnosis at 18 months or three months after breastfeeding ends.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/figure-img-p034-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../images/img-p034-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode with the number 9789240040236.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-074",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "For more information, contact:",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/sec-074-for-more-information-contact.md",
      "narrative": null,
      "content": "World Health Organization\nDepartment of Global HIV, Hepatitis\nand STIs Programmes\nWorld Health Organization\n20, avenue Appia\n1211 Geneva 27\nSwitzerland",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The contact details of the WHO Department of Global HIV, Hepatitis and STIs Programmes in Geneva.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-350214/blocks/prose-sec-075",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "E-mail: hiv-aids@who.int www.who.int/hiv",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/sec-075-e-mail-hiv-aidswhoint-wwwwhointhiv.md",
      "narrative": null,
      "content": "www.who.int/hiv\nISBN 978-92-4-004023-6 (electronic version)\nISBN 978-92-4-004024-3 (print version)\n© World Health Organization 2021. \nSome rights reserved. This work is available under \nthe CC BY-NC-SA 3.0 IGO licence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The back-cover details with WHO HIV contact information, electronic and print ISBNs and the CC BY-NC-SA 3.0 IGO licence, dated 2021.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
